Clinical Trials Logo

Filter by:
NCT ID: NCT06085196 Recruiting - Cognitive Function Clinical Trials

Mindful Walking Program for Older African Americans

Start date: May 16, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to understand the beneficial role of mindful walking in sustaining cognitive health in African American older adults who have elevated risk of developing neuropsychological diseases. The main question it aims to answer is "Does a multi-session mindful walking intervention lead to promising signals of sustaining cognitive health in vulnerable AA older adults?" The researchers in this 2-arm randomized controlled trial will compare the mindful walking group with a delayed mindful walking to see if the intervention efficacy is observed at multiple follow-up period.

NCT ID: NCT06085183 Recruiting - Ureter Injury Clinical Trials

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency in Patient's With Renal Impairment

Start date: December 20, 2023
Phase: Phase 4
Study type: Interventional

This is an open label, randomized, multicenter study to evaluate the efficacy and safety of two dose levels (2.5 mL and 5.0 mL) of Indigotindisulfonate Sodium Injection, USP 0.8% when used as an aid in the determination of ureteral patency in patients with different degrees of renal impairment.

NCT ID: NCT06085144 Recruiting - Migraine Clinical Trials

Emgality for Migraine in Breastmilk

Start date: December 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this project is to evaluate galcanezumab transfer into maternal breastmilk, and to evaluate infant (growth, development, constipation, colic, infections) and maternal (headache) outcomes for dyads in which the mother was treated with galcanezumab and to compare outcomes for infants who were or were not breastfed after maternal treatment. In this prospective observational study, the study team proposes to prospectively collect serial milk samples from 30 adult women who are treated with galcanezumab for migraine. Mothers who are interested in participating will be connected with us, the main clinical site, by neurologists across the USA. Mothers must carry a diagnosis of migraine, be aged 18-45 years, and be between 14 days and 9 months postpartum, and still nursing, at the time of enrollment. This study will fill a significant unmet need as women of childbearing potential are over-represented in the migraine population, and yet they are excluded from clinical trials of migraine treatments during pregnancy and lactation.

NCT ID: NCT06085131 Recruiting - Cataract Clinical Trials

Accuracy of the New Barrett TAL Formula With the Argos Measurements: A Multicenter Prospective Study

Start date: October 31, 2023
Phase:
Study type: Observational

This study is a prospective, multi-site, multi-surgeon, observational study of refractive accuracy with the Argos using BTAL after successful cataract surgery. Subjects will be assessed pre-operatively, operatively and at 5-8 weeks postoperatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and preoperative biometry.

NCT ID: NCT06085092 Recruiting - Anorexia Nervosa Clinical Trials

Open vs. Blind Weighing Study In Adolescents and Young Adult With Eating Disorders

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

Current treatments for adolescents and young adults (AYAs) with eating disorders (EDs) do not effectively address a central ED symptom - anxiety about weight gain - which contributes to poor outcomes. The proposed study evaluates the feasibility, acceptability, efficacy, and underlying mechanisms of an enhanced version of "open weighing," a cognitive-behavioral intervention designed to target anxiety about weight gain in AYAs with EDs. Understanding how to better treat AYAs with EDs, and identifying the mechanisms by which interventions lead to improvement, will aid in the development of more effective and personalized treatments, ultimately improving the lives of AYAs with EDs.

NCT ID: NCT06085079 Recruiting - Uveitis, Posterior Clinical Trials

Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Start date: June 1, 2022
Phase: Phase 4
Study type: Interventional

The objective of this study is to explore the efficacy of ixekizumab in treating patients with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic steroid-dependent anterior uveitis who had failed treatment with a classic synthetic DMARD including methotrexate, mycophenolate, cyclosporin, azathioprine, cyclophosphamide and/or at least one anti-TNF agent including adalimumab, infliximab, etanercept, golimumab or certolizumab.

NCT ID: NCT06084936 Recruiting - Lymphoma Clinical Trials

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

GLOBRYTE
Start date: October 22, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

NCT ID: NCT06084884 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

ATHENA
Start date: November 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.

NCT ID: NCT06084806 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Test-retest Evaluation of [18F]F-AraG PET

Start date: October 31, 2023
Phase: Phase 2
Study type: Interventional

This pilot study aims to evaluate the test-retest variability of [18F]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of [18F]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two [18F]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.

NCT ID: NCT06084780 Not yet recruiting - Clinical trials for Pseudomyxoma Peritonei

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

TRANSCAPE
Start date: October 2024
Phase: Phase 2
Study type: Interventional

The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.